Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 9, 2013, Pages 1115-1137

  Perera, Vidya ^a   Gross, Annette S ^b   M Polasek, Thomas ^c   Qin, Yan ^a   Rao, Gauri ^a   Forrest, Alan ^a   Xu, Junzhe ^d   McLachlan, Andrew J ^e  

^a UNIVERSITY AT BUFFALO   (United States)

^b GLAXOSMITHKLINE   (Australia)

^c FLINDERS UNIVERSITY   (Australia)

^d UNIVERSITY AT BUFFALO   (United States)

^e UNIVERSITY OF SYDNEY   (Australia)

Author keywords

CYP1A2; Drug metabolism; Genotype; Olanzapine; Pharmacokinetics; Phenotype

Indexed keywords

AMITRIPTYLINE; CAFFEINE; CLOMIPRAMINE; CLOZAPINE; CYCLOBENZAPRINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; FLUTAMIDE; FLUVOXAMINE; HALOPERIDOL; IMIPRAMINE; MEXILETINE; NAPROXEN; OLANZAPINE; PROPRANOLOL; RILUZOLE; ROPIVACAINE; TACRINE; THEOPHYLLINE; TIZANIDINE; VERAPAMIL; WARFARIN; ZILEUTON; ZOLMITRIPTAN;

AGE DISTRIBUTION; ALLELE; ASTHMA; BIPOLAR DISORDER; BODY COMPOSITION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; DEPRESSION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG WITHDRAWAL; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MIGRAINE; OSTEOARTHRITIS; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHENOTYPE; PRESCRIPTION; PROTEIN EXPRESSION; PSYCHOSIS; RECOMMENDED DRUG DOSE; REVIEW; RHEUMATOID ARTHRITIS; SCHIZOPHRENIA; SEX DIFFERENCE; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; STEADY STATE; TREATMENT RESPONSE; URINARY EXCRETION; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CYTOCHROME P-450 CYP1A2; DOSE-RESPONSE RELATIONSHIP, DRUG; GENOTYPE; HUMANS; PHARMACOGENETICS; PHENOTYPE; SCHIZOPHRENIA;

EID: 84882438633     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.795540     Document Type: Review

References (230)

1. Liu-Seifert H, Adams DH, Kinon BJ. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. BMC Med 2005;23(3):21
2. Ascher-Svanum H, Nyhuis AW, Stauffer V, et al. Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives. Curr Med Res Opin 2010;26(10):2403-10
3. Hiemke C, Baumann P, Bergemann N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 2011;44(6):195-235
4. Schwenger E, Dumontet J, Ensom MHH. Does Olanzapine Warrant Clinical Pharmacokinetic Monitoring in Schizophrenia? Clin Pharmacokinet 2011;50(7):415-28
5. Patel MX, Bowskill S, Couchman L, et al. Olanzapine Plasma Concentration and Dose: findings from a 10 year review of a therapeutic monitoring service. J Psychopharmacol 2011;25(8):A66-A
6. Lutz R, Kohnlein O, Minov C, et al. Management of the atypical antipsychotic Olanzapine (Zyprexa) in a clinical environment with particular regard to therapeutic drug monitoring (TDM) in a German State Hospital. Pharmacopsychiatry 2003;36(5):245-6
7. Gaertner I, Gaertner HJ, Lampe D. Therapeutic drug monitoring of clozapine and olanzapine. Similarities and differences. Psychopharmakotherapie 1999;Aug;6(3)):105-9
8. Dobmeier M. What are the benefits of TDM in a psychiatric clinic? Results from 5 years of olanzapine monitoring. Ther Drug Monit 2005;27(2):216
9. Faber MS, Jetter A, Fuhr U. Assessment of CYP1A2 activity in clinical practice: why, how, and when? Basic Clin Pharmacol Toxicol 2005;97(3):125-34
10. Hagg S, Spigset O, Lakso HA, et al. Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes. Eur J Clin Pharmacol 2001;57(6-7):493-7
11. Doude van Troostwijk LJ, Koopmans RP, Vermeulen HD, et al. CYP1A2 activity is an important determinant of clozapine dosage in schizophrenic patients. Eur J Pharm Sci 2003;20(4-5):451-7
12. Bigos KL, Pollock BG, Coley KC, et al. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol 2008;48(2):157-65
13. Parise VF, Balletta G, Addeo L, et al. Effectiveness and tolerability of olanzapine long-acting injection versus first-generation depot for schizophrenia: clinical outcomes. Eur Neurol 2011;21:S477-S8
14. Kasper S. Risperidone and olanzapine: optimal dosing for efficacy and tolerability in patients with schizophrenia. Int Clin Psychopharmacol 1998;13(6):253-62
15. Dittmann RW, Meyer E, Freisleder FJ, et al. Effectiveness and tolerability of olanzapine in the treatment of adolescents with schizophrenia and related psychotic disorders: results from a large, prospective, open-label study. J Child Adolesc Psychopharmacol 2008;18(1):54-69
16. Colombo GL, Caruggi M, Di Matteo S, et al. An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. Neuropsychiatr Dis Treat 2008;4(5):967-76
17. L'Italien GJ, Casey DE, Kan HJ, et al. Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo. J Clin Psychiatry 2007;68(10):1510-16
18. Meyer JM, Pandina G, Bossie CA, et al. Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study. Clin Ther 2005;27(12):1930-41
19. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005;352(21):2211-21
20. Huang SM, Temple R. Is this the drug or dose for you? Impact and consideration of ethnic factors in global drug development, regulatory review, and clinical practice. Clin Pharmacol Ther 2008;84(3):287-94
21. Perera V, Gross AS, McLachlan AJ. Influence of environmental and genetic factors on CYP1A2 activity in individuals of South Asian and European Ancestry. Clin Pharmacol Ther 2012;92(4):511-19
22. Perera V, Elmeliegy MA, Rao G, et al. The link between pharmacodynamics and physiologically-based pharmacokinetic models. Clin Pharmacol Ther 2013;93:162-3
23. Callaghan JT, Bergstrom RF, Ptak LR, et al. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999;37(3):177-93
24. Thelen K, Dressman JB. Cytochrome P450-mediated metabolism in the human gut wall. J Pharm Pharmacol 2009;61(5):541-58
25. Krishna DR, Klotz U. Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 1994;26(2):144-60
26. Kalra BS. Cytochrome P450 enzyme isoforms and their therapeutic implications: an update. Indian J Med Sci 2007;61(2):102-16
27. Nelson DR, Kamataki T, Waxman DJ, et al. The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 1993;12(1):1-51
28. Evans WE, McLeod HL. Pharmacogenomics-Drug Disposition, Drug Targets, and Side Effects. N Engl J Med 2003;348:538-49
29. Rowland M, Tozer TN. Basic considerations. Clinical pharmacokinetics and pharmacodynamics. 4th edition. Lippincott Williams & Wilkins; Philadelphia, PA: 2011. p. 839
30. Butler JM, Begg EJ. Free drug metabolic clearance in elderly people. Clin Pharmacokinet 2008;47(5):297-321
31. Aklillu E, Carrillo JA, Makonnen E, et al. Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron Mol Pharmacol 2003;64(3):659-69
32. Butler MA, Lang NP, Young JF, et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics 1992;2(3):116-27
33. Kalow W, Tang BK. The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther 1993;53(5):503-14
34. Takata K, Saruwatari J, Nakada N, et al. Phenotype-genotype analysis of CYP1A2 in Japanese patients receiving oral theophylline therapy. Eur J Clin Pharmacol 2006;62(1):23-8
35. Skinner MH. Adverse reactions and interactions with theophylline. Drug Saf 1990;5(4):275-85
36. Bertilsson L, Carrillo JA, Dahl ML, et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994;38(5):471-3
37. Shirley KL, Hon YY, Penzak SR, et al. Correlation of cytochrome P450 (CYP) 1A2 activity using caffeine phenotyping and olanzapine disposition in healthy volunteers. Neuropsychopharmacology 2003;28(5):961-6
38. Markowitz JS, DeVane CL, Malcolm RJ, et al. Pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers. J Clin Pharmacol 2002;46(2):164-71
39. Olesen OV, Linnet K. Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication. Ther Drug Monit 1999;21(1):87-90
40. Fulton B, Goa KL. Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 1997;53(2):281-98
41. Maenpaa J, Wrighton SA, Bergstrom RF, et al. Pharmacokinetic (PK) and pharmacodynamic (PD) interactions between fluvoxamine and olanzapine. Clin Pharmacol Ther 1997;61:225
42. Linnet K. Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes. Hum Psychopharmacol 2002;17(5):233-8
43. Ring BJ, Catlow J, Lindsay TJ, et al. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 1996;276(2):658-66
44. Kassahun K, Mattiuz E, Nyhart E Jr, et al. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos 1997;25(1):81-93
45. Perera V, Gross AS, McLachlan AJ. Measurement of CYP1A2 Activity: a Focus on Caffeine as a Probe. Curr Drug Metab 2012;13(5):667-78
46. Frye RF. Probing the world of cytochrome P450 enzymes. Molecular Interventions 2004;4(3):157-62
47. Mahner M, Kary M. What exactly are genomes, genotypes and phenotypes? And what about phenomes? J Theor Biol 1997;186(1):55-63
48. Campbell ME, Grant DM, Inaba T, et al. Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. Drug Metab Dispos 1987;15(2):237-49
49. Gu L, Gonzalez FJ, Kalow W, et al. Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics 1992 Apr;2(2)):73-7
50. Perera V, Gross AS, McLachlan AJ. Pharmacokinetics of caffeine in plasma and saliva and the influence of caffeine abstinence on CYP1A2 metrics. J Pharm Pharmacol 2011;63(9):1161-8
51. Rostami-Hodjegan A, Nurminen S, Jackson PR, Tucker GT. Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics 1996;6(2):121-49
52. Fuhr U, Rost KL. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics 1994;4(3):109-16
53. Perera V, Gross AS, McLachlan AJ. Diurnal variation of CYP1A2 Activity in South Asians and Europeans. J Pharm Pharmacol 2012;65(2):264-70
54. Kalow W. Interethnic variation of drug metabolism. Trends Pharmacol Sci 1991;12(3):102-7
55. Le Marchand L, Franke AA, Custer L, et al. Lifestyle and nutritional correlates of cytochrome CYP1A2 activity: inverse associations with plasma lutein and alpha-tocopherol. Pharmacogenetics 1997;7(1):11-19
56. Ghotbi R, Christensen M, Roh HK, et al. Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol 2007;Jun;63(6)):537-46
57. Djordjevic N, Ghotbi R, Bertilsson L, et al. Induction of CYP1A2 by heavy coffee consumption in Serbs and Swedes. Eur J Clin Pharmacol 2008;64(4):381-5
58. Browning SL, Tarekegn A, Bekele E, et al. CYP1A2 is more variable than previously thought: a genomic biography of the gene behind the human drug-metabolizing enzyme. Pharmacogenet Genomics 2010;20(11):647-64
59. Klein K, Winter S, Turpeinen M, et al. Pathway-targeted pharmacogenomics of CYP1A2 in human liver. Front Pharmacol 2010;1:129
60. Jiang Z, Dragin N, Jorge-Nebert LF, et al. Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype. Pharmacogenet Genomics 2006;16(5):359-67
61. Lim JS, Singh O, Ramasamy RD, et al. Pharmacogenetics of CYP1A2, novel polymorphisms and haplotypes in three distinct Asian populations. Drug Metab Pharmacokinet 2010;25(6):616-23
62. Kroon LA. Drug interactions with smoking. Am J Health-Syst Pharm 2007;64(18):1917-21
63. Hoffmann D, Hoffmann I. The changing cigarette, 1950-1995. J Toxicol Environ Health B Crit Rev 1997;50(4):307-64
64. Zevin S, Benowitz NL. Drug Interactions with tobacco smoking. An update. Clin Pharmacokinet 1999;36(3):425-38
65. Gunes A, Ozbey G, Vural EH, et al. Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population. Pharmacogenomics 2009;10(5):769-78
66. Carrillo JA, Herraiz AG, Ramos SI, et al. Role of the smoking-induced cytochrome P450 (CYP)1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J Clin Psychopharmacol 2003;23(2):119-27
67. Dallack GW, Healy DJ, Meador-Woodruff JH. Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am J Psychiatry 1998;155(11):1490-501
68. de Leon J. Atypical antipsychotic dosing: the effect of smoking and caffeine. Psychopharmacology (Berl) 2004;55(5):491-3
69. Beratis S, Katrivanou A, Gourzis P. Factors affecting smoking in schizophrenia. Compr Psychiatry 2001;42(5):393-402
70. Eugster HP, Probst M, Wurgler FE, et al. Caffeine, estradiol, and progesterone interact with human CYP1A1 and CYP1A2. Evidence from cDNA-directed expression in Saccharomyces cerevisiae. Drug Metab Dispos 1993;21(1):43-9
71. Granfors MT, Backman JT, Laitila J, et al. Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. Clin Pharmacol Ther 2005;78(4):400-11
72. Abernethy DR, Todd EL. Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. Eur J Clin Pharmacol 1985;28:425-8
73. Haslemo T, Refsum H, Molden E. The effect of ethinylestradiol-containing contraceptives on the serum concentration of olanzapine and N-desmethyl olanzapine. Br J Clin Pharmacol 2011;71(4):611-15
74. Catteau A, Bechtel YC, Poisson N, et al. A population and family study of CYP1A2 using caffeine urinary metabolites. Eur J Clin Pharmacol 1995;47(5):423-30
75. Becquemont L, Ragueneau I, Le Bot MA, et al. Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. Clin Pharmacol Ther 1997;61(6):619-27
76. Chang WH, Augustin B, Lane HY, et al. In-vitro and in-vivo evaluation of the drug-drug interaction between fluvoxamine and clozapine. Psychopharmacology 1999;145(1)):91-8
77. Christensen M, Tybring G, Mihara K, et al. Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19). Clin Pharmacol Ther 2002;71(3):141-52
78. Granfors MT, Backman JT, Neuvonen M, et al. Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction. [see comment]. Clin Pharmacol Ther 2004;75(4):331-41
79. Jokinen MJ, Ahonen J, Neuvonen PJ, et al. The effect of erythromycin, fluvoxamine, and their combination on the pharmacokinetics of ropivacaine. Anesth Analg 2000;91(5):1207-12
80. Yao C, Kunze KL, Kharasch ED, et al. Fluvoxamine-theophylline interaction: Gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2. Clin Pharmacol Ther 2001;70(5)):415-24
81. Wietholtz H, Zysset T, Kreiten K, et al. Effect of phenytoin, carbamazepine, and valproic acid on caffeine metabolism. Eur J Clin Pharmacol 1989;36(4):401-6
82. Parker AC, Pritchard P, Preston T, et al. Induction of CYP1A2 activity by carbamazepine in children using the caffeine breath test. Br J Clin Pharmacol 1998;45(2):176-8
83. Rost KL, Brosicke H, Brockmoller J, et al. Increase of cytochrome P450IA2 activity by omeprazole: evidence by the 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 1992;52(2):170-80
84. Backman JT, Granfors MT, Neuvonen PJ. Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine. Eur J Clin Pharmacol 2006;62(6):451-61
85. Lucas RA, Gilfillan DJ, Bergstrom RF. A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism. Eur J Clin Pharmacol 1998;54(8):639-43
86. de Jong J, Hoogenboom B, van Troostwijk LD, et al. Interaction of olanzapine with fluvoxamine. Psychopharmacology (Berl) 2001;155(2):219-20
87. Chiu CC, Lane HY, Huang MC, et al. Dose-dependent alternations in the pharmacokinetics of olanzapine during coadministration of fluvoxamine in patients with schizophrenia. J Clin Pharmacol 2004;44(12):1385-90
88. McLachlan AJ, Pont LG. Drug metabolism in older people-A key consideration in achieving optimal outcomes with medicines. J Gerontol A Biol Sci Med Sci 2012;67(2):175-80
89. Cooper WO, Arbogast PG, Ding H, et al. Trends in prescribing of antipsychotic medications for US children. Ambul Pediatr 2006;6(2):79-83
90. Bozikas VP, Papakosta M, Niopas I, et al. Smoking impact on CYP1A2 activity in a group of patients with schizophrenia. Eur Neuropsychopharmacol 2004;14(1):39-44 A pivotal study which demonstrates the importance of smoking on CYP1A2 activity in patients with schizophrenia.
91. Horn EP, Tucker MA, Lambert G, et al. A study of gender-based cytochrome P4501A2 variability: a possible mechanism for the male excess of bladder cancer. Cancer Epidemiol Biomarkers Prev 1995;4(5):529-33
92. Ozdemir V, Kalow W, Posner P, et al. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentration in patients with schizophrenia. J Clin Psychopharmacol 2001;21(4):398-407
93. Gunes A, Dahl M-L. Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. Pharmacogenomics 2008;9(5):625-37
94. Simon T, Becquemont L, Hamon B, et al. Variability of cytochrome P450 1A2 activity over time in young and elderly healthy volunteers. Br J Clin Pharmacol 2001;52(5):601-4
95. Mayayo-Sinues E, Fanlo A, Sinues B, et al. Lack of effect of growth hormone replacement therapy on CYP1A2 and xanthine oxidase activities in growth hormone-deficient children. Eur J Clin Pharmacol 2006;62(2):123-7
96. Masimirembwa CM, Beke M, Hasler JA, et al. Low CYP1A2 activity in rural Shona children of Zimbabwe. Clin Pharmacol Ther 1995;57(1):25-31
97. Lambert GH, Schoeller DA, Kotake AN, et al. The effect of age, gender, and sexual maturation on the caffeine breath test. Dev Psychobiol 1986;9(6):375-88
98. Kennedy MJ, Davis DA, Smith N, et al. Reduced activities of cytochrome P450 1A2 and xanthine oxidase in children with growth hormone deficiency. Clin Pharmacol Ther 2008;84(6):674-8
99. Begas E, Kouvaras E, Tsakalof A, et al. In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios. Biomed Chromatogr 2007;21(2):190-200
100. Rasmussen BB, Brosen K. Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans. Ther Drug Monit 1996;18(3):254-62
101. Sachse C, Bhambra U, Smith G, et al. Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br J Clin Pharmacol 2003;55(1):68-76
102. Scandlyn MJ, Stuart EC, Rosengren RJ. Sex-specific differences in CYP450 isoforms in humans. Expert Opin Drug Metab Toxicol 2008;4(4):413-24
103. Relling MV, Lin JS, Ayers GD, et al. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities. Clin Pharmacol Ther 1992;52(6):643-58
104. Bartoli A, Xiaodong S, Gatti G, et al. The influence of ethnic factors and gender on CYP1A2-mediated drug disposition: a comparative study in Caucasian and Chinese subjects using phenacetin as a marker substrate. Ther Drug Monit 1996;18(5):586-91
105. Zaigler M, Rietbrock S, Szymanski J, et al. Variation of CYP1A2-dependent caffeine metabolism during menstrual cycle in healthy women. Int J Clin Pharmacol Ther 2000;38(5):235-44
106. Carrillo JA, Benitez J. CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine. Brit J Clin Pharmacol 1996;Jun;41(6)):605-8
107. Bartoli A, Xiaodong S, Gatti G, et al. The influence of ethnic factors and gender on CYP1A2-mediated drug disposition: a comparative study in Caucasian and Chinese subjects using phenacetin as a marker substrate. Ther Drug Monit 1996;18(5):586-91
108. Backman JT, Schroder MT, Neuvonen PJ. Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine. Eur J Clin Pharmacol 2008;64:17-24
109. Limited ELaC, inventor Zyprexa. Summary of product characteristics. Basingstoke, UK. 2006
110. Weiss U, Marksteiner J, Kemmler G, et al. Effects of age and sex on olanzapine plasma concentrations. J Clin Psychopharmacol 2005;25(6):570-4
111. Skogh E, Reis M, Dahl ML, et al. Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting. Ther Drug Monit 2002;24(4):518-26
112. Gex-Fabry M, Balant-Gorgia AE, Balant LP. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit 2003;25(1):46-53
113. Aichhorn W, Marksteiner J, Walch T, et al. Age and gender effects on olanzapine and risperidone plasma concentrations in children and adolescents. J Child Adolesc Psychopharmacol 2007;17(5):665-74
114. Parker AC, Pritchard P, Preston T, et al. Induction of CYP1A2 activity by carbamazepine in children using the caffeine breath test. Br J Clin Pharmacol 1998;45(2):176-8
115. Kennedy E, Kumar A, Datta SS. Antipsychotic medication for childhood-onset schizophrenia. Cochrane Database Syst Rev 2007(3):CD004027
116. Kelly DL, Conley RR, Tamminga CA. Differential olanzapine plasma concentrations by sex in a fixed-dose study. Schizophr Res 1999;40(2):101-4
117. Manschreck TC, Boshes RA. The CATIE schizophrenia trial: results, impact, controversy. Harv Rev Psychiatry 2007;15(5):245-58
118. Chen X, Wang L, Zhi L, et al. The G-113A polymorphism in CYP1A2 affects the caffeine metabolic ratio in a Chinese population. Clin Pharmacol Ther 2005;78(3):249-59
119. Nakajima M, Yokoi T, Mizutani M, et al. Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol Biomarkers Prev 1994;3(5):413-21
120. Soyama A, Saito Y, Hanioka N, et al. Single nucleotide polymorphisms and haplotypes of CYP1A2 in a Japanese population. Drug Metab Pharmacokinet 2005;20(1):24-33
121. Basvi PT, Dandara C, Bapiro T, et al. Role of CYP1A21F on CYP1A2 activity in a black African population as determined by caffeine phenotyping. Am J Chin Med 2007;2(4):211-14
122. Kalow W, Tang BK. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 1991;50(5 Pt 1):508-19
123. Subramaniam M, Ng C, Chong SA, et al. Metabolic differences between Asian and Caucasian patients on clozapine treatment. Hum Psychopharm 2007 Jun;22(4)):217-22
124. Tantcheva-Poor I, Zaigler M, Rietbrock S, et al. Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. Pharmacogenetics 1999;9(2):131-44
125. Zhou S-F, Liu J-P, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 2009;41(2):89-295
126. Nebert DW. Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? Am J Hum Genet 1997;60(2):265-71
127. Zanger UM, Turpeinen M, Klein K, et al. Functional pharmacogenetics/ genomics of human cytochromes P450 involved in drug biotransformation. Analyt Biochem 2008 Nov;392(6)):1093-108
128. http://www.cypalleles.ki.se/cyp1a2.htm [Accessed 21 September 2012]
129. MacLeod S, Tang Y-M, Yokoi T, et al. The role of recently discovered genetic polymorphism in the regulation of the human CYP1A2 gene. Proc Am Assoc Cancer Res 1998;39:1
130. Sachse C, Brockmoller J, Bauer S, et al. Functional significance of a C-> A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999;47(4):445-9
131. Chida M, Yokoi T, Fukui T, et al. Detection of three genetic polymorphisms in the 5'-flanking region and intron 1 of human CYP1A2 in the Japanese population. Jpn J Cancer Res 1999;90(9):899-902
132. Hamdy SI, Hiratsuka M, Narahara K, et al. Genotyping of four genetic polymorphisms in the. CYP1A2 gene in the Egyptian population. Br J Clin Pharmacol 2003;55(3):321-4
133. Tiwari AK, Deshpande SN, Lerer B, et al. Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: V. Association of CYP1A2 1545 C>T polymorphism. Pharmacogenomics J 2007;7(5):305-11
134. Todesco L, Torok M, Krahenbuhl S, et al. Determination of-3858G->A and-164C->A genetic polymorphisms of CYP1A2 in blood and saliva by rapid allelic discrimination: large difference in the prevalence of the-3858G-> A mutation between Caucasians and Asians. Eur J Clin Pharmacol 2003;59(4):343-6
135. Cornelis MC, El-Sohemy A, Kabagambe EK, et al. Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA 2006;295(10):1135-41
136. Dandara C, Basvi PT, Bapiro TE, et al. Frequency of-163 C>A and 63 C>G single nucleotide polymorphism of cytochrome P450 1A2 in two African populations. Clin Chem Lab Med 2004;42(8):939-41
137. Dobrinas M, Cornuz J, Oneda B, et al. Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility. Clin Pharmacol Ther 2011;90(1):117-25
138. Djordjevic N, Ghotbi R, Jankovic S, et al. Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2-163C>A polymorphism. Eur J Clin Pharmacol 2010;66(7):697-703
139. Nordmark A, Lundgren S, Ask B, et al. The effect of the CYP1A2 1F mutation on CYP1A2 inducibility in pregnant women. Br J Clin Pharmacol 2002;54(5):504-10
140. Larsen JT, Brosen K. Consumption of charcoal-broiled meat as an experimental tool for discerning CYP1A2-mediated drug metabolism in vivo. Basic Clin Pharmacol Toxicol 2005;97(3):141-8
141. Shimoda K, Someya T, Morita S, et al. Lack of impact of CYP1A2 genetic polymorphism (C/A polymorphism at position 734 in intron 1 and G/A polymorphism at position-2964 in the 5'-flanking region of CYP1A2) on the plasma concentration of haloperidol in smoking male Japanese with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2002;26(2):261-5
142. Chen L, Bondoc FY, Lee MJ, et al. Caffeine induces cytochrome P4501A2: induction of CYP1A2 by tea in rats. Drug Metab Dispos 1996 May;24(5)):529-33
143. Berthou F, Goasduff T, Dreano Y, et al. Caffeine increases its own metabolism through cytochrome P4501A induction in rats. Life Sci 1995;57(6):541-9
144. Landi MT, Zocchetti C, Bernucci I, et al. Cytochrome P4501A2: enzyme induction and genetic control in determining 4-aminobiphenyl-hemoglobin adduct levels. Cancer Epidemiol Biomarkers Prev 1996;5(9):693-8
145. Dobrinas M, Cornuz J, Pedrido L, et al. Influence of cytochrome P450 oxidoreductase genetic polymorphisms on CYP1A2 activity and inducibility by smoking. Pharmacogenet Genomics 2012;22(2):143-51
146. Rasmussen BB, Brix TH, Kyvik KO, et al. The interindividual differences in the 3-demthylation of caffeine alias CYP1A2 is determined by both genetic and environmental factors. Pharmacogenetics 2002;12(6):473-8
147. Spigset O, Hagg S, Soderstrom E, et al. The paraxanthine:caffeine ratio in serum or in saliva as a measure of CYP1A2 activity: when should the sample be obtained? Pharmacogenetics 1999;9(3):409-12
148. Sinues B, Fanlo A, Bernal ML, et al. Influence of the urine flow rate on some caffeine metabolite ratios used to assess CYP1A2 activity. Ther Drug Monit 2002;24(6):715-21
149. Sinues B, Saenz MA, Lanuza J, et al. Five caffeine metabolite ratios to measure tobacco-induced CYP1A2 activity and their relationships with urinary mutagenicity and urine flow. Cancer Epidem Biomarkers Prev 1999;8(2):159-66
150. Cornelis MC, El-Sohemy A, Campos H. Genetic polymorphism of CYP1A2 increases the risk of myocardial infarction. J Med Genet 2004;41(10):758-62
151. Cornelis MC, Bae SC, Kim I, et al. CYP1A2 genotype and rheumatoid arthritis in Koreans. Rheumatol Int 2010;30(10):1349-54
152. Rodenburg EM, Eijgelsheim M, Geleijnse JM, et al. CYP1A2 and coffee intake and the modifying effect of sex, age, and smoking. Am J Clin Nutr 2012;96(1):182-7
153. Hallstrom H, Melhus H, Glynn A, et al. Coffee consumption and CYP1A2 genotype in relation to bone mineral density of the proximal femur in elderly men and women: a cohort study. Nutr Metab 2010;7:12
154. Wickliffe JK, Abdel-Rahman SZ, Lee C, et al. CYP1A21F and GSTM1 alleles are associated with susceptibility to porphyria cutanea tarda. Mol Med 2011;17(3-4):241-7
155. Palatini P, Ceolotto G, Ragazzo F, et al. CYP1A2 genotype modifies the association between coffee intake and the risk of hypertension. J Hypertens 2009;27(8):1594-601
156. Guessous I, Dobrinas M, Kutalik Z, et al. Caffeine intake and CYP1A2 variants associated with high caffeine intake protect non-smokers from hypertension. Hum Mol Genet 2012 Jul;15;21(14)):3283-92
157. Bageman E, Ingvar C, Rose C, et al. Coffee consumption and CYP1A21F genotype modify age at breast cancer diagnosis and estrogen receptor status. Cancer Epidemiol Biomarkers Prev 2008;17(4):895-901
158. Balibey H, Basoglu C, Lundgren S, et al. CYP1A21F Polymorphism Decreases Clinical Response to Clozapine in Patients with Schizophrenia. BCP 2011;21(2):93-9
159. Basile VS, Ozdemir V, Masellis M, et al. A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol Psychiatry 2000;5(4):410-17
160. Ferrari M, Bolla E, Bortolaso P, et al. Association between CYP1A2 polymorphisms and clozapine-induced adverse reactions in patients with schizophrenia. Psychiatry Res 2012;200(2-3):1014-7
161. Laika B, Leucht S, Heres S, et al. Pharmacogenetics and olanzapine treatment: CYP1A21F and serotonergic polymorphisms influence therapeutic outcome. Pharmacogenomics J 2010;10(1):20-9
162. Rajkumar AP, Poonkuzhali B, Kuruvilla A, et al. Association between CYP1A2 gene single nucleotide polymorphisms and clinical responses to clozapine in patients with treatment-resistant schizophrenia. Acta Neuropsychiatr 2012; Early View Online
163. Schulze TG, Schumacher J, Muller DJ, et al. Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia. Am J Med Genet 2001;105(6):498-501
164. Soderberg M. Clinical pharmacogenetics of olanzapine with focus on FMO gene polymorphisms. Uppsala Universitet; Uppsala: 2012
165. Skogh E, Sjodin I, Josefsson M, et al. High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug. J Clin Psychopharmacol 2011;31(1):4-9
166. Nozawa M, Ohnuma T, Matsubara Y, et al. The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: juntendo University Schizophrenia Projects (JUSP). Ther Drug Monit 2008;30(1):35-40
167. Ghotbi R, Mannheimer B, Aklillu E, et al. Carriers of the UGT1A4 142T > G gene variant are predisposed to reduced olanzapine exposure-an impact similar to male gender or smoking in schizophrenic patients. Eur J Clin Pharmacol 2010;66(5):465-74
168. Jiang Z, Dragin N, Jorge-Nebert LF, et al. Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotype. Pharmacogenet Genomics 2006;16(5):359-67
169. Johnson JA, Burkley BM, Langaee TY, et al. Implementing personalized medicine: development of a cost-effective customized pharmacogenetics genotyping array. Clin Pharmacol Ther 2012;92(4):437-9
170. Reynolds KS. Achieving the promise of personalized medicine. Clin Pharmacol Ther 2012;92(4):401-5
171. Whirl-Carrillo M, McDonagh EM, Hebert JM, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 2012;92(4):414-17
172. Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 2006;58(3):521-90
173. Ghotbi R, Gomez A, Milani L, et al. Allele-specific expression and gene methylation in the control of CYP1A2 mRNA level in human livers. Pharmacogenomics J 2009;9(3):208-17
174. Palma BB, Silva ESM, Vosmeer CR, et al. Functional characterization of eight human cytochrome P450 1A2 gene variants by recombinant protein expression. Pharmacogenomics J 2010;10(6):478-88
175. Grant DM, Tang BK, Kalow W. Variability in caffeine metabolism. Clin Pharmacol Ther 1983;33(5):591-602
176. Lesko LJ, Schmidt S. Individualization of drug therapy: history, present state, and opportunities for the future. Clin Pharmacol Ther 2012;92(4):458-66
177. Forrest A, Ballow CH, Nix DE, et al. Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob Agents Chemother 1993;37(5):1065-72
178. Ette EI, Williams PJ. Population pharmacokinetics I: background, concepts, and models. Ann Pharmacother 2004;38(10):1702-6
179. Bradley JS, Garonzik SM, Forrest A, et al. Pharmacokinetics, pharmacodynamics, and Monte Carlo simulation: selecting the best antimicrobial dose to treat an infection. Pediatr Infect Dis J 2010;29(11):1043-6
180. Sherwin CM, Saldana SN, Bies RR, et al. Population pharmacokinetic modeling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescents. Ther Drug Monit 2012;34(5):535-44
181. Olesen OV, Linnet K. Metabolism of the tricyclic antidepressant amitriptyline by cDNA-expressed human cytochrome P450 enzymes. Pharmacology 1997;55(5):235-43
182. Hartter S, Arand M, Oesch F, et al. Non-competitive inhibition of clomipramine N-demethylation by fluvoxamine. Essent Psychopharmacol 1995;117(2):149-53
183. Lemoine A, Gautier JC, Azoulay D, et al. Major pathway of imipramine metabolism is catalyzed by cytochromes P-450 1A2 and P-450 3A4 in human liver. Mol Pharmacol 1993;43(5):827-32
184. Wang H-X, Ma X-C, Deng Q-L, et al. Cytotoxicity of flutamide and 2-hydroxyflutamide and their effects on CYP1A2 mRNA in primary rat hepatocytes. Acta Pharmacol Sin 2002;23(6):562-6
185. Carrillo JA, Dahl ML, Svensson JO, et al. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther 1996;60(2):183-90
186. Pirmohamed M, Williams D, Madden S, et al. Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther 1995;272(3):984-90
187. Pan L, Belpaire FM. In vitro study on the involvement of CYP1A2, CYP2D6 and CYP3A4 in the metabolism of haloperidol and reduced haloperidol. Eur J Clin Pharmacol 1999;55(8):599-604
188. Shirley KL, Hon YY, Penzak SR, et al. Correlation of cytochrome P450 (CYP) 1A2 activity using caffeine phenotyping and olanzapine disposition in healthy volunteers. Neuropsychopharmacol 2003 May;28(5)):961-6
189. Butler MA, Iwasaki M, Guengerich FP, et al. Human cytochrome P-450PA (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 1989;86(20):7696-700
190. Ha HR, Chen J, Freiburghaus AU, et al. Metabolism of theophylline by cDNA-expressed human cytochromes P-450. Br J Clin Pharmacol 1995;39(3):321-6
191. Rasmussen BB, Brosen K. Theophylline has no advantages over caffeine as a putative model drug for assessing CYPIA2 activity in humans. Br J Clin Pharmacol 1997;43(3):253-8
192. Salyers KL, Barr J, Sipes IG. In vitro metabolism of theophylline by rat and human liver tissue. Xenobiotica 1994;24(5):389-99
193. Wang RW, Liu L, Cheng H. Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. Drug Metab Dispos 1996;24(7):786-91
194. Arlander E, Ekstrom G, Alm C, et al. Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: an interaction study with fluvoxamine and ketoconazole as in vivo inhibitors. Clin Pharmacol Ther 1998;64(5):4-91
195. Larsen J, Hansen L, Brosen K. Tacrine is not an ideal probe drug for meauring CYP1A2 activity in vivo. Br J Clin Pharmacol 1999;48(5):663-8
196. Spaldin V, Madden S, Adams DA, et al. Determination of human hepatic cytochrome P4501A2 activity in vitro use of tacrine as an isoenzyme-specific probe. Drug Metab Dispos 1995;23(9):929-34
197. Sanderink GJ, Bournique B, Stevens J, et al. Involvement of human CYP1A isoenzymes in the metabolism and drug interactions of riluzole in vitro. J Pharmacol Exp Ther 1997;282(3):1465-72
198. Granfors MT, Backman JT, Neuvonen M, et al. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. Clin Pharmacol Ther 2004;76(6):598-606
199. Nakajima M, Kobayashi K, Shimada N, et al. Involvement of CYP1A2 in mexiletine metabolism. Br J Clin Pharmacol 1998;46(1):55-62
200. Masubuchi Y, Hosokawa S, Horie T, et al. Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metab Dispose 1994;22(6):909-15
201. Kroemer HK, Gautier JC, Beaune P, et al. Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol 1993;348(3):332-7
202. Miners JO, Coulter S, Tukey RH. Cytochromes P450, 1A2, and 2C9 are responsible for the human hepatic O-demethylation of R-and S-naproxen. Biochem Pharmacol 1996 Apr;26;51(8)):1003-8
203. Wild MJ, McKillop D, Butters CJ. Determination of the human cytochrome P450 isoforms involved in the metabolism of zolmitriptan. Xenobiotica 1999;29(8):847-57
204. Yu L-S, Yao T-W, Zeng S. In vitro metabolism of zolmitriptan in rat cytochromes induced with beta-naphthoflavone and the interaction between six drugs and zolmitriptan. Chem Biol Interact 2003;146(3):263-72
205. Ngui JS, Chen Q, Shou M, et al. In vitro stimulation of warfarin metabolism by quinidine: increases in the formation of 4'-and 10-hydroxywarfarin. Drug Metab Dispos 2001;29(6):877-86
206. Zhang Z, Fasco MJ, Huang Z, et al. Human cytochromes P4501A1 and P4501A2: R-warfarin metabolism as a probe. Drug Metab Dispos 1995;23(12):1339-46
207. Lu P, Schrag ML, Slaughter DE, et al. Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos 2003;31(11):1352-60
208. Han XM, Ou-Yang DS, Lu PX, et al. Plasma caffeine metabolite ratio (17X/137X) in vivo associated with G-2964A and C734A polymorphisms of human CYP1A2. Pharmacogenetics 2001;11(5):429-35
209. Begas E, Kouvaras E, Tsakalof A, et al. In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios. Biomed Chromatogr 2007;21(2):190-200
210. Castorena-Torres F, Mendoza-Cantu A, de Leon MB, et al. CYP1A2 phenotype and genotype in a population from the carboniferous region of Coahuila, Mexico. Toxicol Lett 2005. Apr 28. 156(3): 331-9
211. Gunes A, Ozbey G, Vural EH, et al. Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population. Pharmacogenomics 2009;10(5):769-78
212. Chen X, Wang L, Zhi L, et al. The G-113A polymorphism in CYP1A2 affects the caffeine metabolic ratio in a Chinese population. Clin Pharmacol Ther 2005;78(3):249-59
213. Chevalier D, Cauffiez C, Allorge D, et al. Five novel natural allelic variants-951A>C, 1042G>A (D348N), 1156A>T (I386F), 1217G>A (C406Y) and 1291C>T (C431Y)-of the human CYP1A2 gene in a French Caucasian population. Hum Mutat 2001;17(4):355-6
214. Lim J, Singh O, Ramasamy R, et al. Pharmacogenetics of CYP1A2, novel polymorphisms and haplotypes in three distinct Asian populations. Drug Metab Pharmacokinet 2010;25(6):616-23
215. Sachse C, Bhambra U, Smith G, et al. Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br J Clin Pharmacol 2003;55(1):68-76
216. Soyama A, Saito Y, Hanioka N, et al. Single nucleotide polymorphisms and haplotypes of CYP1A2 in a Japanese population. Drug Metab Pharmacok 2005;20(1):24-33; Erratum appears in Drug Metab Pharmacokinet. 2005 Apr;20(2):152
217. Ghotbi R, Christensen M, Roh H-K, et al. Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol 2007;63(6):537-46
218. Hamdy SI, Hiratsuka M, Narahara K, et al. Genotyping of four genetic polymorphisms in the CYP1A2 gene in the Egyptian population. Br J Clin Pharmacol 2003;55(3):321-4
219. Han X-M, Ouyang D-S, Chen X-P, et al. Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2. Br J Clin Pharmacol 2002;54(5):540-3
220. Nakajima M, Yokoi T, Mizutani M, et al. Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem 1999;125(4):803-8
221. Pavanello S, B'Chir F, Pulliero A, et al. Interaction between CYP1A2-T2467DELT polymorphism and smoking in adenocarcinoma and squamous cell carcinoma of the lung. Lung Cancer 2007;57(3):266-72
222. Tiwari AK, Deshpande SN, Lerer B, et al. Genetic susceptibility to Tardive Dyskinesia in chronic schizophrenia subjects: V. Association of CYP1A2 1545 C>T polymorphism. Pharmacogenomics J 2007;7(5):305-11
223. Todesco L, Torok M, Krahenbuhl S, et al. Determination of-3858G->A and-164C->A genetic polymorphisms of CYP1A2 in blood and saliva by rapid allelic discrimination: large difference in the prevalence of the-3858G-> A mutation between Caucasians and Asians. Eur J Clin Pharmacol 2003;59(4):343-6
224. Chida M, Yokoi T, Fukui T, et al. Detection of three genetic polymorphisms in the 5'-flanking region and intron 1 of human CYP1A2 in the Japanese population. Jpn J Cancer Res 1999;90(9):899-902
225. Sachse C, Brockmoller J, Bauer S, et al. Functional significance of a C-> A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 1999;47(4):445-9
226. Aklillu E, Carrillo JA, Makonnen E, et al. Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron Mol Pharmacol 2003;64(3):659-69
227. Takata K, Saruwatari J, Nakada N, et al. Phenotype-genotype analysis of CYP1A2 in Japanese patients receiving oral theophylline therapy. Eur J Clin Pharmacol 2006;62(1):23-8
228. Cornelis MC, El-Sohemy A, Kabagambe EK, et al. Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA 2006;295(10):1135-41
229. Dandara C, Basvi PT, Bapiro TE, et al. Frequency of-163 C>A and 63 C>G single nucleotide polymorphism of cytochrome P450 1A2 in two African populations. Clin Chem Lab Med 2004;42(8):939-41
230. Fujihara J, Shiwaku K, Xue Y, et al. CYP1A2 polymorphism (C > A at position-163) in Ovambos, Koreans and Mongolians. Cell Biochem Funct 2007;25(5):491-4